(168 days)
No
The document describes standard fetal monitoring technology (ultrasound Doppler, TOCO, DECG, IUPC) and connectivity options. There is no mention of AI, ML, or any advanced analytical capabilities beyond basic signal processing. The "Mentions AI, DNN, or ML" section explicitly states "Not Found".
No.
A therapeutic device is used for treatment. This device is a monitor used for diagnosis and monitoring, not for treatment.
Yes
The device is used for monitoring fetal health indicators like heart rate and uterine activity, which are observed to determine the status of the fetus and pregnant woman. This falls under the definition of diagnosing a health condition or physiological state.
No
The device description explicitly mentions hardware components like ultrasound Doppler, external TOCO transducer, direct fetal ECG technique, and an Intrauterine Pressure Catheter, which are used for data acquisition. It also mentions physical interfaces like RJ45 and DB9.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Fetal Monitor described here is used for monitoring the fetus and uterine activity externally using ultrasound and TOCO transducers, or internally using DECG and IUPC. These methods involve direct interaction with the patient or internal monitoring within the body, not testing samples taken from the body.
- Intended Use: The intended use is for "non-invasive and invasive monitoring of fetus during antepartum examination, labor and delivery." This clearly describes a monitoring function, not a diagnostic test performed on a sample.
Therefore, the Fetal Monitor is a medical device used for physiological monitoring, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The F2 and F3 Fetal Monitor are intended for non-invasive and invasive monitoring of fetus during antepartum examination, labor and delivery. They are intended to be used only by trained and qualified personnel in antepartum examination rooms, labor and delivery rooms.
They both provide Non-stress testing for pregnant women from the 28th week of gestation. They can externally monitor the FHRs using ultrasound and uterine activity via a TOCO transducer. Alternatively, they can internally monitor one of the FHRs with DECG and uterine activity with an IUPC.
Product codes
HGM, HGL
Device Description
With non-invasive ultrasound Doppler, external TOCO and direct fetal ECG technique, Fetal Monitor provides Non-Stress testing for pregnant women from the 28th week of gestation. You can externally monitor the fetal heart rate using ultrasound and uterine activity via a TOCO transducer. Alternatively, you can internally monitor one of the fetal heart rate with direct fetal ECG technique and uterine activity with an Intrauterine Pressure Catheter.
The Fetal Monitor has six models: Cadence, Cadence DUAL, Cadence PRO, Cadence II, F2 and F3. The former four models Cadence, Cadence DUAL, Cadence PRO, Cadence II have already been cleared under K082369, while the other two models F2, F3 are new models of Fetal Monitor in this Traditional 510(K) application, which have the same intended use and constructions to the existing models.
The Fetal monitor can be connected with Central Monitoring System via RJ45 interface. Also it can be connected to wireless network module via a DB9 interface, and the wireless network module will complete the data switch of the monitor and the Obstetrical Central Monitoring System.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Ultrasound Doppler
Anatomical Site
Not Found
Indicated Patient Age Range
pregnant women from the 28th week of gestation
Intended User / Care Setting
trained and qualified personnel in antepartum examination rooms, labor and delivery rooms.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Verification and validation testing was done on the Fetal Monitor models F2, F3. This premarket notification submission demonstrates that Fetal Monitor models F2, F3 is substantially equivalent to the predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 884.2740 Perinatal monitoring system and accessories.
(a)
Identification. A perinatal monitoring system is a device used to show graphically the relationship between maternal labor and the fetal heart rate by means of combining and coordinating uterine contraction and fetal heart monitors with appropriate displays of the well-being of the fetus during pregnancy, labor, and delivery. This generic type of device may include any of the devices subject to §§ 884.2600, 884.2640, 884.2660, 884.2675, 884.2700, and 884.2720. This generic type of device may include the following accessories: Central monitoring system and remote repeaters, signal analysis and display equipment, patient and equipment supports, and component parts.(b)
Classification. Class II (performance standards).
0
F2, F3 Fetal Monitors TRADITIONAL 510(K) SUBMISSION
Section 1
510(k) Summary of Safety and Effectiveness
JAN 1 3 201
This summary of 510k safety and effectiveness is being submitted in according with 21CFR part 807.92
Submitter: Edan Instruments, Inc 3/F - B, Nanshan Medical Equipments Park, Nanhai Rd 1019#, shekou, Nanshan Shenzhen, 518067 P.R. China Tel: 86-755-26882220. . . . . . . . . . . . . Fax:86-755-26882223 Contact person: Yue Qiuhong Official correspondent: William Stern Multigon Industries, Inc. 1 Odell Plaza Yonkers, N.Y. 10701 Phone: 914 376 5200 X27 Fax: 914 376 6111 Date of Preparation: 2010-7-22 Proprietary Name: F2, F3 Fetal Monitor (Models: F2, F3) Classification Name: System, Monitoring, Perinatal Product code: HGM, HGL Predicate Devices:
| Predicate devices | CADENCE, CADENCE DUAL,
CADENCE II FETAL MONITOR |
|-------------------|----------------------------------------------------|
| Manufacturer | Edan Instruments, Inc |
| K # | K082369 |
Device Description:
With non-invasive ultrasound Doppler, external TOCO and direct fetal ECG technique, Fetal Monitor provides Non-Stress testing for pregnant women from the 28th week of gestation. You can externally monitor the fetal heart rate using ultrasound and uterine activity via a TOCO transducer. Alternatively, you can internally monitor one of the fetal heart rate with direct fetal ECG technique and uterine activity with an Intrauterine Pressure Catheter.
1
F2, F3 Fetal Monitors TRADITIONAL 510(K) SUBMISSION ·
Section 1
The Fetal Monitor has six models: Cadence, Cadence DUAL, Cadence PRO, Cadence II, F2 and F3. The former four models Cadence, Cadence DUAL, Cadence PRO, Cadence II have already been cleared under K082369, while the other two models F2, F3 are new models of Fetal Monitor in this Traditional 510(K) application, which have the same intended use and constructions to the existing models.
The Fetal monitor can be connected with Central Monitoring System via RJ45 interface. Also it can be connected to wireless network module via a DB9 interface, and the wireless network module will complete the data switch of the monitor and the Obstetrical Central Monitoring System.
Comparison with predicate device .
The F2, F3 fetal monitors have the same device characteristics as the predicate approved device cleared under K082369. Both models use the same technology and circuitry as the already approved device models Cadence, Cadence DUAL, Cadence PRO, Cadence II cleared under K082369. Hence the models F2, F3 above are substantially equivalent to the predicate devices cited.
Intended Use
The F2, F3 Fetal Monitor are intended for non-invasive and invasive monitoring of fetus during antepartum examination, labor and delivery. They are intended to be used only by trained and qualified personnel in antepartum examination rooms, labor and delivery rooms.
They both provide Non-stress testing for pregnant women from the 28th week of gestation. They can externally monitor the FHRs using ultrasound and uterine activity via a TOCO transducer. Alternatively, they can internally monitor one of the FHRs with DECG and uterine activity with an IUPC.
Contraindications:
It is not intended for use in intensive care units, operating rooms or for home use.
Test Summary:
The following quality assurance measures were applied to the development of the F2, F3 Fetal Monitors.
- · Software testing
- · Hardware testing
- · Safety testing
- · Environment test
- · Risk analysis · · ..
- · Final validation
Conclusion:
Verification and validation testing was done on the Fetal Monitor models F2, F3. This premarket notification submission demonstrates
5/22
2
, KIDZL 40 , કર્ભ રે page
F2, F3 Fetal Monitors TRADITIONAL 510(K) SUBMISSION
Section 1
that Fetal Monitor models F2, F3 is substantially equivalent to the predicate device.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo features a stylized image of an eagle with its wings spread, enclosed within a circular border. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged around the border of the circle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Mr. Yue Qiuhong Certification Engineer Edan Instruments, Inc. 3/F-B, Nanshan Medical Equipment Park Nanhai Road 1019# Shenzhen, Guangdong, 518067 CHINA
APR 2 6 2012
K102140 Re:
Trade/Device Name: Fetal Monitor model F2 and F3 Regulation Number: 21 CFR § 884.2740 Regulation Name: Perinatal monitoring system and accessories Regulatory Class: II Product Code: HGM, HGL Dated: December 20, 2010 Received: December 27, 2010
Dear Mr. Oiuhong:
This letter corrects our substantially equivalent letter of January 13, 2011.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
This determination of substantial equivalence applies to the following transducers intended for use with the Fetal Monitor model F2 and F3, as described in your premarket notification:
MS3-109301
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found
4
Page 2 - Mr. Yue Oiuhong
in the Code of Federal Regulations, Title 21, Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
If you have any questions regarding the content of this letter, please contact Ms. Kathryn Daws- Kopp at (301) 796-6535. は
Sincerely yours,
t
Herbert Hoover
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosures
5
F2, F3 Fetal Monitors TRADITIONAL 510(K) SUBMISSION
Section 1
Indication for Use
510(k) Number (if.known):
Device Name: F2, F3 Fetal Monitors (Models: F2, F3)
The F2 and F3 Fetal Monitor are intended for non-invasive and invasive monitoring of fetus during antepartum examination, labor and delivery. They are intended to be used only by trained and qualified personnel in antepartum examination rooms, labor and delivery rooms.
They both provide Non-stress testing for pregnant women from the 28th week of gestation. They can externally monitor the FHRs using ultrasound and uterine activity via a TOCO transducer. Alternatively, they can internally monitor one of the FHRs with DECG and uterine activity with an IUPC.
× Prescription Use (21 CFR Part 801 Subpart D)
And/Or Over the Counter Use _ (21 CFR Part 801 Subpart C)
Concurrence of CDRH, Office of Device Evaluation (ODE)
ivision Sign
of Reproductive. Gastro-R
6
Diagnostic Ultrasound indications for Use Form Fill out one form for each ultrasound system and each transducer. 1MHz PW fetal probe
Intended use : Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows
| Clinical Application | Mode Operation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | M | PWD | CWD | Color | ||||||
| Doppler | Amplitude | ||||||||||
| Doppler | Color | ||||||||||
| Velocity | |||||||||||
| Imaging | Combined | ||||||||||
| (specify) | Other | ||||||||||
| (specify) | |||||||||||
| Ophthalmic | |||||||||||
| Fetal | P | ||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| Intraoperative Neurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | |||||||||||
| Neonatal Cephalic | |||||||||||
| Cardiac | |||||||||||
| Transesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| Peripheraln Vascular | |||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletal | |||||||||||
| Conventional | |||||||||||
| Musculo-skeletal Superficial | |||||||||||
| Other |
ndication; P=previously cleared by FDA; e=ADDED UNDER appendix E Additional Comments: _________________________________________________________________________________________________________________________________________________________
The above is a 1MHz PW transducer for the fetal heart rate detection
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE I PNEEDED CONCURRENCE OF cdrh, Office of Device Evaluation (ODE)
Tracy
r. 13, 2012
Section 1